-
JAMA Netw Open: Is there any abuse of opioid analgesics in patients with chronic non-cancerous pain (CNCP)?
Time of Update: 2021-04-17
The main results and measurements of the study include: high-dose opioid use (200mg/d of oral morphine); request to increase the dose of opioid; request to update the prescription in advance; tamper with opioid; transfer the drug to others; and "Disease and Related Opioid dependence as defined in the tenth revised edition of the International Statistical Classification of Health Problems.
-
Br J Cancer: 5-Aminosalicylic Acid: Candidate for Prevention of Colorectal Polyps and Colorectal Cancer
Time of Update: 2021-04-17
Screening prevention In this study, the researchers aimed to investigate the potential of 5-ASA (5-aminosalicylic acid, a drug used to treat medsci.
The researchers said that 5-ASA, which is reasonably priced and well-tolerated, is a potential drug candidate for chemoprevention, which can reduce the risk of colorectal polyps and CRC in high-risk populations.
-
NEJM: Levatinib-Pembrolizumab is better than sunitinib in the treatment of advanced renal cell carcinoma
Time of Update: 2021-04-17
66)The study found that for patients with advanced renal cell carcinoma, levatinib-pembrolizumab treatment has a significant advantage compared with sunitinib in improving the progression-free survival and overall survival of patients.
-
Phase III clinical study CheckMate -816 results released: Odivo® (Navulimab) combined with chemotherapy as a neoadjuvant treatment for patients with resectable non-small cell lung cancer can significantly improve tumor pathology and complete remission
Time of Update: 2021-04-17
The results showed that compared with chemotherapy alone, patients with stage Ib to IIIa resectable non-small cell lung cancer who received 3 cycles of Odivo combined chemotherapy treatment before surgery can significantly improve tumor pathological complete remission ( pCR ) and achieve major Study endpoint.
-
Eur Radiol: For liver metastases, we can find more!
Time of Update: 2021-04-17
Gadoxetate disodium-enhanced MRI has extremely high sensitivity and specificity in the detection of liver metastases from colorectal cancer (CRC), pancreatic adenocarcinoma (PDAC) and neuroendocrine tumors (NET).
The primary lesions in 60 patients were colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC) or neuroendocrine tumor (NET).
-
The CD38 inhibitor Sarclisa/Carfilzomib/Dexamethasone (Kd) for the treatment of advanced multiple myeloma has been approved by the FDA
Time of Update: 2021-04-17
Manage FDASarclisa (isatuximab) combined with Kd therapy is currently used in the United States to treat adult patients with relapsed or refractory multiple myeloma (RR MM), these patients have received one to three previous treatment options.
-
JCO: The effect of adjuvant chemotherapy on the quality of life of elderly patients with HER2-positive breast cancer
Time of Update: 2021-04-17
Using the Comprehensive Cancer Therapy Functional Assessment Scale (FACT-G), Philadelphia Geriatric Center Morale Scale, Hospital Anxiety and Depression Scale, Patient Neurotoxicity Questionnaire, and Tokyo Metropolitan Institute of Geriatrics Competency Index at baseline and after treatment 2, 12, 36 The quality of life assessment is carried out every month.
-
J Clin Invest: H3.3K27M specific vaccine response in diffuse midline glioma
Time of Update: 2021-04-17
3K27M targeted peptide vaccine, and the results have been published in J Clin Invest.
3K27M-specific vaccine responses in diffuse midline gliom .
3K27M-specific vaccine responses in diffuse midline gliom in this message
-
Lancet respirat med: Efficacy analysis of pembrolizumab in the treatment of late-period skin tumors
Time of Update: 2021-04-17
Pembrolizumab showed initial clinical benefit in MPM positive for programmed death ligand 1 (PD-L1)The Phase 2 KEYNOTE-158 study is an ongoing open-label, multi-cohort, single-arm Phase 2 trial that recruits 18-year-olds who are intolerant to standard treatment or who have progressed after treatment, and have EOCG performance status 0-1 Points, MPM patients with tumor samples that can be assessed for biomarkers.
-
AACR Annual Meeting: Neoadjuvant immunotherapy will increase the pathological complete response rate of NSCLC patients by 12 times!
Time of Update: 2021-04-17
Recently, the results of the randomized, phase III, open-label CheckMate 816 trial announced at the 2021 virtual annual meeting of the American Association for Cancer Research (AACR) showed that compared with chemotherapy alone, the neoadjuvant immunotherapy drug nivolumab plus platinum Dual chemotherapy significantly increased the pathological complete response (pCR) rate in patients with resectable stage IB to IIIA non-small cell lung cancer ( NSCLC ).
-
JNNP: A prospective study of cancer survival in patients with HuD antibody-related paraneoplastic neurological diseases
Time of Update: 2021-04-17
However, in previous retrospective studies, the survival rate of patients with Hu antibody-related PNDs (Hu-Ab/PNDs) was similar to that of patients with small cell lung cancer (SCLC) without neurological disease.
-
JCO: Prognosis of children with adrenocortical carcinoma of different stages treated with various regimens
Time of Update: 2021-04-17
childA prospective single-arm risk-stratification intervention study published recently in " J Clin Oncol " outlines (1) the prognosis of stage I ACC patients undergoing adrenalectomy alone, (2) adrenalectomy and retroperitoneal lymph nodes The prognosis of dissected stage II patients (complete resection >200 cc or >100 g), (3) the prognosis of stage III or IV patients receiving mitotane and chemotherapy.
-
NATURE: Subversion!
Time of Update: 2021-04-17
However, in TME, it is still unclear whether there is a metabolic disorder of immune cells caused by the internal program of the cell or competition with cancer cells for limited nutrients.
-
Nat Med: Peripheral immune characteristics of PD-1 block response in patients with classic Hodgkin's lymphoma
Time of Update: 2021-04-16
gov/32778827/" target="_blank" rel="noopener">A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma .
gov/32778827/" target="_blank" rel="noopener">A peripheral immune signature of responsiveness to PD -1 blockade in patients with classical Hodgkin lymphoma in this message
-
Intratumoral heterogeneity may become another important marker of lung cancer immunotherapy
Time of Update: 2021-04-16
html" target="_blank">biomarkers In the past ten years, immune checkpoint inhibitors (ICIs) have made significant progress in the clinical treatment of tumors.
In order to solve this clinical problem and enable more patients to benefit from treatment, Professor Zhang’s team optimized the algorithm of intratumoral heterogeneity and verified that bioon.
-
JAMA Oncol: Tislelizumab combined with chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer has a significant effect
Time of Update: 2021-04-16
In conclusion, in this phase 3 randomized clinical trial, regardless of the expression of PD-L1, for patients with advanced sq NSCLC, the addition of Tislelizumab and IRC to chemotherapy significantly prolonged PFS, higher ORR, and better safety/resistance.
-
CD47 monoclonal antibody is beginning to show its strength!
Time of Update: 2021-04-16
In 2020, a local biopharmaceutical company and the world's top ten pharmaceutical companies AbbVie reached a strategic cooperation worth nearly 3 billion U. S. dollars. This "alarming" cooperation i
-
J Immunother Cancer: Antibiotics have a significant negative effect on the prognosis of NSCLC patients treated with pembrolizumab!
Time of Update: 2021-04-16
In unselected patients with non-small cell lung cancer ( NSCLC ) , some concomitant drugs , including antibiotics (ATB), are related to poor survival of immune checkpoint inhibitor (ICI) treatment, and the correlation is reproducible NSCLC Antibiotic ImmunizationAn article published recently in " J Immunother Cancer " of " Journal of Cancer Immunotherapy " outlines a large-scale study of patients with metastatic NSCLC who received first-line pembrolizumab monotherapy with PD-L1 expression of ≥50%.
-
BeiGene Guangzhou Biopharmaceutical Production Base was officially opened, allowing Chinese patients to enjoy international-quality anticancer drugs
Time of Update: 2021-04-16
In addition, 1 Yue 12 Ri, NMPA has approved its anti- PD-1 antibody Chak one hundred ® ( tislelizumab , for Reilly natalizumab injection) joint 2 Xiang chemotherapy for first-line treatment of advanced squamous non-small cell lung cancer ( NSCLC )patient.
-
Br J Cancer: The level of estrogen in urine can be used as a risk indicator for the development of prostate cancer
Time of Update: 2021-04-16
The results of the study revealed that urine levels of estriol and 16-ketoestradiol metabolites are associated with more favorable outcomes for patients, while 2-methoxyestrone levels are associated with increased risk of metastasis after RP Related.
